Etretinate

Etretinate

Clinical data
AHFS/Drugs.com	Micromedex Detailed Consumer Information
MedlinePlus	a601010
Routes of administration	Oral
ATC code	D05BB01 (WHO)
Pharmacokinetic data
Elimination half-life	120 days
Identifiers
IUPAC name ethyl 9-(4-methoxy-2,3,6-trimethyl-phenyl)- 3,7-dimethyl-nona- 2,4,6,8-tetraenoate
CAS Number	54350-48-0 N
PubChem CID	5282375
DrugBank	DB00926 Y
ChemSpider	4445538 Y
UNII	65M2UDR9AG
KEGG	D00316 Y
ChEBI	CHEBI:4913 Y
ChEMBL	ChEMBL464 Y
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C23H30O3
Molar mass	354.483 g/mol
3D model (JSmol)	Interactive image
SMILES O=C(OCC)\C=C(\C=C\C=C(\C=C\c1c(cc(OC)c(c1C)C)C)C)C
InChI InChI=1S/C23H30O3/c1-8-26-23(24)14-17(3)11-9-10-16(2)12-13-21-18(4)15-22(25-7)20(6)19(21)5/h9-15H,8H2,1-7H3/b11-9+,13-12+,16-10+,17-14+ Y Key:HQMNCQVAMBCHCO-DJRRULDNSA-N Y
NY (what is this?)  (verify)

WikiDoc Resources for Etretinate
Articles
Most recent articles on Etretinate Most cited articles on Etretinate Review articles on Etretinate Articles on Etretinate in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Etretinate Images of Etretinate Photos of Etretinate Podcasts & MP3s on Etretinate Videos on Etretinate
Evidence Based Medicine
Cochrane Collaboration on Etretinate Bandolier on Etretinate TRIP on Etretinate
Clinical Trials
Ongoing Trials on Etretinate at Clinical Trials.gov Trial results on Etretinate Clinical Trials on Etretinate at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Etretinate NICE Guidance on Etretinate NHS PRODIGY Guidance FDA on Etretinate CDC on Etretinate
Books
Books on Etretinate
News
Etretinate in the news Be alerted to news on Etretinate News trends on Etretinate
Commentary
Blogs on Etretinate
Definitions
Definitions of Etretinate
Patient Resources / Community
Patient resources on Etretinate Discussion groups on Etretinate Patient Handouts on Etretinate Directions to Hospitals Treating Etretinate Risk calculators and risk factors for Etretinate
Healthcare Provider Resources
Symptoms of Etretinate Causes & Risk Factors for Etretinate Diagnostic studies for Etretinate Treatment of Etretinate
Continuing Medical Education (CME)
CME Programs on Etretinate
International
Etretinate en Espanol Etretinate en Francais
Business
Etretinate in the Marketplace Patents on Etretinate
Experimental / Informatics
List of terms related to Etretinate

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Etretinate (trade name Tegison) is a medication developed by Hoffmann–La Roche that was approved by the FDA in 1986 to treat severe psoriasis. It is a second-generation retinoid. It was subsequently removed from the Canadian market in 1996 and the United States market in 1998 due to the high risk of birth defects. It remains on the market in Japan.

Properties

Etretinate has a low therapeutic index and a long elimination half-life (t_1/2) of 120 days, which make dosing difficult.

Etretinate is an aromatic retinoid, and therefore highly lipophilic. It is stored and released from adipose tissue, so its effects can continue long after dosage stops. It is detectable in the plasma for up to three years following therapy.

Etretinate has been replaced by acitretin, a safer metabolite of etretinate.

Precautions

• Etretinate is a teratogen, and may cause birth defects long after use. Therefore, birth control is advised during therapy, and for at least three years after therapy has stopped.
• Etretinate should be avoided in children, as it may interfere with bone growth.

• If a patient has ever taken etretinate, he or she is not eligible to donate blood, due to the risk of birth defects.

Side effects

• Hepatitis
• Pseudotumor cerebri
• Diffuse idiopathic skeletal Hyperostosis

History

The drug was approved by the FDA in 1986 to treat severe psoriasis. It was subsequently removed from the Canadian market in 1996 and the United States market in 1998 due to the high risk of birth defects.

In Japan, the drug remains on market branded Tigason. People may not donate blood for two years after ceasing to use the medication.

See also

• List of withdrawn drugs

References

Template:Dermatologic-drug-stub